Evidence map›Paper›PMID 39250525›Full record

ArticlePLoS pathogens2024

Immunization of cows with HIV envelope trimers generates broadly neutralizing antibodies to the V2-apex from the ultralong CDRH3 repertoire.

Pilar X Altman, Gabriel Ozorowski, Robyn L Stanfield, Jeremy Haakenson, Michael Appel, Mara Parren, Wen-Hsin Lee, Huldah Sang, Jordan Woehl, Karen Saye-Francisco and 12 more

Abstract read
In one paragraph

Article in PLoS pathogens, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors.

Pilar X AltmanDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, United States of America.ORCID 0000-0002-2909-0666
Gabriel OzorowskiConsortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, California, United States of America.
Robyn L StanfieldDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California, United States of America.
Jeremy HaakensonDepartment of Molecular Medicine, The Scripps Research Institute, La Jolla, California, United States of America.
Michael AppelIAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, United States of America.
Mara ParrenDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, United States of America.
Wen-Hsin LeeDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California, United States of America.
Huldah SangDepartment of Diagnostic Medicine/Pathobiology, College of Veterinary Medical, Kansas State University, Manhattan, Kansas, United States of America.
Jordan WoehlIAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, United States of America.
Karen Saye-FranciscoDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, United States of America.
Leigh M SewallDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California, United States of America.
Collin JoyceDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, United States of America.
Ge SongDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, United States of America.
Katelyn PorterDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, United States of America.
Elise LandaisIAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, United States of America.
Raiees AndrabiDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, United States of America.
Ian A WilsonConsortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, California, United States of America.
Andrew B WardConsortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, California, United States of America.
Waithaka MwangiDepartment of Diagnostic Medicine/Pathobiology, College of Veterinary Medical, Kansas State University, Manhattan, Kansas, United States of America.
Vaughn V SmiderDepartment of Molecular Medicine, The Scripps Research Institute, La Jolla, California, United States of America.
Dennis R BurtonDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, United States of America.
Devin SokConsortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, California, United States of America.ORCID 0000-0002-9354-1740

Funding

Identification of neutralizing epitopes on SARS-CoV-2 spike for design of vaccines and small-molecule antiviralsUM1AI144462 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BURTON, DENNIS R. · 2019 to 2025
$201.6M
VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SUSAN JANET LITTLE · 1994 to 2026
$78.4M
A Synchrotron Radiation Structural Biology ResourcesP30GM133894 · NIGMS · STANFORD UNIVERSITY · PI Aina E. Cohen, KEITH O HODGSON · 2020 to 2026
$43.3M
User Training & OutreachP30GM138396 · NIGMS · UCHICAGO ARGONNE, LLC · PI ROBERT F. FISCHETTI, JANET L. SMITH · 2020 to 2026
$34.3M
Combining germline-targeting, B cell immunofocusing and Env-Ab coevolution strategies to induce HIV Envelope V2-apex broadly neutralizing antibodiesR61AI161818 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI ANDRABI, RAIEES AHMAD, SHAW, GEORGE M · 2021 to 2023
$4.7M
High-Speed High-Sensitivity Detector for X-ray Micro-Crystallography at GM/CA@APSS10OD012289 · OD · UNIVERSITY OF CHICAGO · PI FISCHETTI, ROBERT F. · 2014 to 2014
$2.0M
Pilatus 6mS10OD021832 · OD · UNIVERSITY OF CALIFORNIA BERKELEY · PI ADAMS, PAUL DAVID · 2016 to 2016
$980k
NIAID NIH HHS P30 AI036214NIAID NIH HHS R61 AI161818NIAID NIH HHS UM1 AI144462NIGMS NIH HHS P30 GM133894NIGMS NIH HHS P30 GM138396NIH HHS S10 OD012289NIH HHS S10 OD021832
6 · The paper itself

Abstract

The generation of broadly neutralizing antibodies (bnAbs) to conserved epitopes on HIV Envelope (Env) is one of the cornerstones of HIV vaccine research. The animal models commonly used for HIV do not reliably produce a potent broadly neutralizing serum antibody response, with the exception of cows. Cows have previously produced a CD4 binding site response by homologous prime and boosting with a native-like Env trimer. In small animal models, other engineered immunogens were shown to focus antibody responses to the bnAb V2-apex region of Env. Here, we immunized two groups of cows (n = 4) with two regimens of V2-apex focusing Env immunogens to investigate whether antibody responses could be generated to the V2-apex on Env. Group 1 was immunized with chimpanzee simian immunodeficiency virus (SIV)-Env trimer that shares its V2-apex with HIV, followed by immunization with C108, a V2-apex focusing immunogen, and finally boosted with a cross-clade native-like trimer cocktail. Group 2 was immunized with HIV C108 Env trimer followed by the same HIV trimer cocktail as Group 1. Longitudinal serum analysis showed that one cow in each group developed serum neutralizing antibody responses to the V2-apex. Eight and 11 bnAbs were isolated from Group 1 and Group 2 cows, respectively, and showed moderate breadth and potency. Potent and broad responses in this study developed much later than previous cow immunizations that elicited CD4bs bnAbs responses and required several different immunogens. All isolated bnAbs were derived from the ultralong CDRH3 repertoire. The finding that cow antibodies can target more than one broadly neutralizing epitope on the HIV surface reveals the generality of elongated structures for the recognition of highly glycosylated proteins. The exclusive isolation of ultralong CDRH3 bnAbs, despite only comprising a small percent of the cow repertoire, suggests these antibodies outcompete the long and short CDRH3 antibodies during the bnAb response.

Indexed as

AIDS VaccinesAntibodies, Neutralizingenv Gene Products, Human Immunodeficiency VirusHIV-1HIV AntibodiesAnimalsBroadly Neutralizing AntibodiesCattleEpitopesFemaleHIV InfectionsHumansImmunizationSimian Immunodeficiency VirusAIDS VaccinesAntibodies, NeutralizingBroadly Neutralizing Antibodiesenv Gene Products, Human Immunodeficiency VirusEpitopesHIV Antibodies

Identifiers

PMID39250525
PMCPMC11412654

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.